Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 1

1(25.0%)

4Total

N/A(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07292025Phase 1Completed

Phase 1 Trial of JTM201 in Subjects With Post-stroke Upper Limb Spasticity

Role: lead

NCT07265778Not ApplicableActive Not Recruiting

Clinical Investigation for Evaluating the Safety and Efficacy of JTM102 to Mid Face Volume Deficiency

Role: lead

NCT07265791Not ApplicableNot Yet Recruiting

Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds

Role: lead

NCT07150273Not ApplicableCompleted

A Clinical Study to Evaluate the Efficacy and Safety of the Injection With UNIVELO Sub-Q, as Compared to Restylane® Sub-Q, in the Temporary Correction of the Nasolabial Fold

Role: lead

NCT06699147Completed

Evaluate the Post-marketing Efficacy and Safety of Eptq S and Eptq Lidocaine S

Role: lead

All 5 trials loaded